Memozam

Memozam is a subgroup of nootropic substances and psychostimulants. It is a complex drug. Its active ingredients are piracetam (a cyclic derivative of γ-aminobutyric acid) and cinnarizine (a selective antagonist of Ca channels).

The drug improves conductivity within the synapses of neocortical structures, as well as communication between the cerebral hemispheres. With prolonged administration of the drug, people with weakened brain activity experience an improvement in attention and cognitive abilities. [ 1 ]

Indications Memozam

It is used as a supportive agent for disorders of cerebrovascular origin, including disorders of thinking function and memory, mood disorders (irritability) and impaired concentration.

It is prescribed as a supportive substance for manifestations of labyrinthine disorders, including tinnitus, vomiting, dizziness, nausea and nystagmus.

It is also used in cases of Meniere's syndrome, and also to prevent the development of migraines and motion sickness.

Release form

The substance is released in capsules - 10 pieces in a blister pack; in a box - 3 or 6 such packs.

Pharmacodynamics

It is likely that Memozam has several mechanisms of medicinal action:

• correction of the speed of movement of excitation impulses within the brain;
• potentiation of metabolic processes within neuronal cells;
• improvement of microcirculation processes by influencing the rheological properties of blood, without developing a vasodilating effect.

Piracetam is a nootropic substance that affects the brain. It helps improve cognitive activity (memory, learning, attention) and intellectual performance. [ 2 ]

Cinnarizine inhibits contraction of smooth vascular muscle cells by blocking the activity of Ca channels. In addition to direct antagonism with respect to Ca, cinnarizine reduces the contractile function of vasoactive elements (serotonin with norepinephrine) by blocking the endings of Ca channels controlled by them. The severity of blockade of cellular Ca entry is determined by the type of tissue. As a result, an antivasoconstrictor effect develops without affecting the level of heart rate and blood pressure. [ 3 ]

Furthermore, cinnarizine is able to improve weak microcirculation by increasing the elasticity of the erythrocyte wall and reducing blood viscosity. There is also an increase in the resistance of cells to hypoxia.

Cinnarizine inhibits the processes of stimulation of the vestibular system activity, which suppresses the development of nystagmus and other autonomic disorders. At the same time, cinnarizine prevents the development of severe dizziness.

Dosing and administration

The capsules should be taken orally, after meals, with plain water and swallowed without chewing.

In case of cerebral blood flow disorders and balance disorders, take 1 capsule of the drug 3 times a day.

In case of motion sickness, take 1 capsule 30 minutes before a walk. Repeat the intake at 6-hour intervals.

• Application for children

It is prohibited to prescribe the drug in pediatrics.

Use Memozam during pregnancy

Memozam should not be used during breastfeeding or pregnancy.

Piracetam can be excreted in breast milk, which is why if you need to use the drug, you should stop breastfeeding.

Contraindications

Main contraindications:

• severe intolerance to cinnarizine with piracetam, as well as other auxiliary elements of the drug;
• severe renal failure;
• active phase of cerebral blood flow disorder (hemorrhagic stroke);
• Huntington's syndrome;
• parkinsonism;
• increase in IOP indicators;
• agitation of a psychomotor nature.

Side effects Memozam

Side effects include:

• disorders of the nervous system: insomnia, hyperkinesia, headaches and ataxia; in addition, there may be a possibility of worsening epilepsy, tremor, dyskinesia, vestibular disorders, hypersomnia, fatigue, balance disorder, lethargy, parkinsonism and an increase in the frequency of epileptic seizures. Long-term administration to the elderly may provoke extrapyramidal symptoms;
• immune disorders: severe intolerance, including anaphylaxis;
• disorders associated with the digestive system: dyspepsia, diarrhea, xerostomia, vomiting, abdominal pain, nausea, cholestatic jaundice and hypersalivation;
• epidermal disorders: rashes, hyperhidrosis, lichen planus and systemic lupus erythematosus, angioedema, itching, photosensitivity, urticaria, dermatitis and keratosis lichenoides;
• mental health problems: anxiety, increased excitability, confusion, drowsiness, hallucinations and depression;
• lesions of the musculoskeletal structure: muscle rigidity;
• symptoms associated with the labyrinth and auditory organs: dizziness appears occasionally;
• reproductive function and mammary gland dysfunction: libido increases occasionally;
• Others: thrombophlebitis, asthenia, hyperthermia and increased blood pressure. Long-term administration of the drug may occasionally lead to weight gain.

Overdose

Poisoning causes potentiation of the drug's side effects. Rarely, acute intoxication may cause signs of dyspepsia (abdominal pain and bloody diarrhea), vomiting, altered consciousness (ranging from drowsiness to stupor and coma), extrapyramidal symptoms, and decreased blood pressure. In children, overdose usually causes symptoms of agitation - anxiety, tremor, euphoria, insomnia, and irritability; convulsions, nightmares, and hallucinations may occasionally occur.

Memozam has no antidote. Gastric lavage should be performed within the first 60 minutes of taking the drug. Activated carbon is prescribed if necessary. Symptomatic measures are also taken. Hemodialysis can be performed.

Interactions with other drugs

The administration of the drug with alcoholic beverages, tricyclics or substances that depress the central nervous system causes a potentiation of the sedative effect.

The medication enhances the therapeutic activity of antihypertensive drugs and vasodilators, as well as nootropic substances.

The effect of Memozam is potentiated when used together with vasodilators; cinnarizine weakens the effect of antihypertensive drugs.

The drug potentiates the effects of thyroid hormones, which can cause the development of anxiety and tremors.

The drug potentiates the effect of orally administered anticoagulants.

Due to the antihistamine activity of the drug, a positive reaction regarding epidermal reactivity factors may be masked during the skin test. Because of this, the drug should be discontinued 4 days before the test.

Storage conditions

Memoses should be stored in a place closed to small children. Temperature indicators - no higher than 30°C.

Shelf life

Memozam can be used within 24 months from the date of sale of the medicinal product.

Analogues

The analogs of the drug are Olatropil, Evrizam with Neuro-norm, Fezam and Noozam, and in addition Thiocetam with Cinatropil and Omaron.